Consensus guidelines for the diagnosis and treatment of multiple sclerosis

Current Medical Research and Opinion

Volumn 29, Issue 6, 2013, Pages 611-621

  Yamout, B ^a   Alroughani, R ^b   Al Jumah, M ^c   Khoury, S ^a   Abouzeid, N ^a   Dahdaleh, M ^d   Alsharoqi, I ^e   Inshasi, J ^f   Hashem, S ^g   Zakaria, M ^h   Elkallab, K ⁱ   Alsaadi, T ^j   Tawfeek, T ^g   Bohlega, S ^k  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Amiri Hospital and Dasman Research Institution   (Kuwait)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d Khalidi Hospital Medical Center   (Jordan)

^e SALMANIYA MEDICAL COMPLEX   (Bahrain)

^f DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^g CAIRO UNIVERSITY   (Egypt)

^h AIN SHAMS UNIVERSITY   (Egypt)

ⁱ University Hospital   (Lebanon)

^j SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^k KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

more..

Author keywords

Diagnosis; Guidelines; Middle East; Multiple sclerosis; Treatment

Indexed keywords

ALEMTUZUMAB; ANTINUCLEAR ANTIBODY; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MYCOPHENOLIC ACID; NATALIZUMAB; RITUXIMAB;

ACUTE LEUKEMIA; ADD ON THERAPY; ALOPECIA; AMENORRHEA; ARTICLE; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSENSUS; DEMYELINATING DISEASE; DISEASE COURSE; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGIC CYSTITIS; HUMAN; INFERTILITY; LEUKOPENIA; LIVER TOXICITY; METASTASIS; MIDDLE EAST; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRACTICE GUIDELINE; RELAPSE; RETINA MACULA EDEMA; RISK ASSESSMENT; SPINAL CORD DISEASE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MIDDLE EAST; MULTIPLE SCLEROSIS; MYELITIS; OPTIC NERVE DISEASES; OPTIC NEURITIS; PROPYLENE GLYCOLS; SPHINGOSINE; SPINAL CORD DISEASES;

EID: 84877262906     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.787979     Document Type: Article

References (95)

1. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552-68
2. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
4. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69: 292-302
5. Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of 'no better explanation'. Lancet Neurol 2006;5:841-52
6. Kelly SB, Chaila E, Kinsella K, et al. Using atypical symptoms and red flags to identify non-demyelinating disease. J Neurol Neurosurg Psychiatry 2012; 83:44-8
7. De Seze J. Atypical forms of optic neuritis. Rev Neurol (Paris) 2012;168: 697-701
8. Giesser BS. Diagnosis of multiple sclerosis. Neurol Clin 2011;29:381-8
9. Filippi M, Rocca MA. The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. Acta Neurol Belg 2011;111:89-98
10. Palace J. Guidelines for differential diagnosis of suspected multiple sclerosis. Nat Clin Pract Neurol 2009;5:134-5
11. Brinar VV, Habek M. Rare infections mimicking MS. Clin Neurol Neurosurg 2010;112:625-8
12. Köhler W. Diagnostic algorithm for the differentiation of leukodystrophies in early MS. J Neurol 2008;255(Suppl 6):123-6
13. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (4):CD001331
14. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86
15. Magañ a SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011;68:870-878
16. Habek M, Barun B, PureticZ, Brinar VV. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial 2010;14:298-302
17. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004;63:1081-3
18. Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009;73:949-53
19. Trebst C, Reising A, Kielstein JT, et al. Plasma exchange therapy in steroidunresponsive relapses in patients with multiple sclerosis. Blood Purif 2009;28:108-15
20. Yücesan C, Arslan O, Arat M, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci 2007;36:103-7
21. Rodriguez M, Karnes WE, Bartleson JD, et al. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993;43:1100-4
22. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300
23. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Metaanalysis Group. Lancet 1999;353:964-9
24. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116(Pt 1):135-46
25. Rocca MA, Agosta F, Sormani MP, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255:683-91
26. Tintoré M, Rovira A, Ŕo J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72
27. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131(Pt 3):808-17
28. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-8
29. Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010;16:156-65
30. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol;65:727-32
31. Patrucco L, Rojas JI, Cristiano E. Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol 2011;259:1317-20
32. Mowry EM, Deen S, Malikova I, et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80:400-3
33. Villar LM, Garća-Barragán N, Sadaba MC, et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 2008;266:34-7
34. Morrow SA, Fraser JA, Nicolle D, et al. Predicting conversion to MS-the role of a history suggestive of demyelination. Can J Neurol Sci 2010;37:488-91
35. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64
36. Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009;119:126-30
37. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
38. Comi G, Filippi M, Barkhof F, et al.; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
39. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
40. Comi G, Martinelli V, Rodegher M, et al.; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
41. O'connor P, Kinkel RP, Kremenchutzky M. Efficacy of IM intereferon beta 1 a in patients with CIS analysis of subgroups based on new risk criteria. Multiple Sclerosis 2009;15:728-34
42. Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008;(2):CD005278
43. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655-61
44. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39: 285-94
45. The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
46. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
47. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;(4):CD002002
48. Kappos L, Radue EW, O'Connor P, et al.; FREEDOMS Study Group. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
49. Cohen JA, Barkhof F, Comi G, et al.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
50. Del Santo F, Maratea D, Fadda V, et al. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Eur J Clin Pharmacol 2012;68:441-8
51. Polman CH, O'Connor PW, Havrdova E, et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
52. Rudick RA, Stuart WH, Calabresi PA, et al.; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
53. Hutchinson M, Kappos L, Calabresi PA, et al.; AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256: 405-15
54. Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011;(10):CD007621
55. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
56. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58
57. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011;258:1920-8
58. Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:742-50
59. Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012;53:65-71
60. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303
61. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352: 1491-7
62. Kappos L, Polman C, Pozzilli C, et al.; European Study Group in Interferon beta-1b in Secondary-Progressive MS. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001;57:1969-75
63. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95
64. Cohen JA, Cutter GR, Fischer JS, et al.; IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87
65. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferonbeta-1a in secondary progressive MS: clinical results. Neurology 2001; 56:1496-504
66. Hartung HP, Gonsette R, König N, et al.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-25
67. Zipoli V, Portaccio E, Hakiki B, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2008;266:25-30
68. Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004;218:73-7
69. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40
70. Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004;27:80-3
71. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001;248:713-14
72. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60: 44-51
73. Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004;10(Suppl 1): S62,62-4
74. Wolinsky JS, Narayana PA, O'Connor P, et al.; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24
75. Cadavid D, Kim S, Peng B, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler 2011;17:1113-21
76. Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011;259: 659-81
77. Gauthier SA, Glanz BI, Mandel M, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009;284:116-19
78. Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009;25:2459-70
79. Healy BC, Glanz BI, Stankiewicz J, et al. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler 2010;16:1483-9
80. Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011;77: 1684-90
81. Prosperini L, Borriello G, De Giglio L, et al. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of interferon beta dose should be effective BMC Neurol 2011;11:26
82. Panitch H, Goodin DS, Francis G, et al.; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506
83. Durelli L, Verdun E, Barbero P, et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359: 1453-60
84. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009;23:379-96
85. Aarskog NK, Marøy T, Myhr KM, et al. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol 2009;212:148-50
86. Farrell RA, Espasandin M, Lakdawala N, et al. Incorporation of an interferon-neutralizing antibody assay into routine clinical practice. Mult Scler 2011;17:1333-40
87. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740-50
88. Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009;8:519-29
89. Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9:672-80
90. Prosperini L, Gianǹ C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012;18:64-71
91. Lanzillo R, Quarantelli M, Bonavita S, et al. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand 2011;126:306-14
92. Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol 2011;52:321-30
93. Fernandez-Meǵa MJ, Casanova B, Magraner MJ, et al. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. Farm Hosp 2011;35:75-9
94. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004;63(12 Suppl 6):S8-14
95. Khan OA, Zvartau-Hind M, Caon C, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001;7:185-8